rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Alpha Cognition Inc.

ACOG · Nasdaq

Health CareBiotechnologyLeading

ACOG stood above a rising 150-day average in 17 of the last 52 weekly readings, including each of the last 17 weeks. It is 13.6% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
17 in a row
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$15.7M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
26 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 17 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$3.1MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months51
Sale orders, 12 months0
Buyers · sellers3 · 0
WhoDidSharesTraded
Opaleye Management Inc.10% ownerbought14,283at $8.2316 Oct 2026filed 19 Oct 2026
Opaleye Management Inc.10% ownerbought22,657at $8.4315 Oct 2026filed 19 Oct 2026
Opaleye Management Inc.10% ownerbought19,050at $8.691 Oct 2026filed 2 Oct 2026
Opaleye Management Inc.10% ownerbought13,426at $8.4725 Sep 2026filed 28 Sep 2026
Opaleye Management Inc.10% ownerbought18,337at $8.5724 Sep 2026filed 28 Sep 2026
Opaleye Management Inc.10% ownerbought53,029at $8.5716 Sep 2026filed 16 Sep 2026
Opaleye Management Inc.10% ownerbought27,141at $8.4016 Sep 2026filed 16 Sep 2026
Opaleye Management Inc.10% ownerbought3,375at $8.5415 Sep 2026filed 16 Sep 2026
Opaleye Management Inc.10% ownerbought40,373at $8.7014 Sep 2026filed 16 Sep 2026
Robert James WillsDirectorbought10,000at $9.6221 Aug 2026filed 24 Aug 2026
Opaleye Management Inc.10% ownerbought50,000at $8.003 Aug 2026filed 4 Aug 2026
Opaleye Management Inc.10% ownerbought2,900at $7.9231 Jul 2026filed 4 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders26+1 on the quarter
New · exited1 · 0
Reported value$75.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Opaleye Management Inc.added · filed 14 Aug 20262,895,467$20.9M+333,517+13.0%
Solas Capital Management, LLCunchanged · filed 14 Aug 20261,924,617$13.9M00.0%
AWM Investment Company, Inc.unchanged · filed 14 Aug 20261,672,168$12.1M00.0%
Cable Car Capital, LPunchanged · filed 14 Aug 20261,382,339$10.0M00.0%
Ikarian Capital, LLCreduced · filed 14 Aug 2026836,259$6.0M-220,000−20.8%
SPHERA FUNDS MANAGEMENT LTD.reduced · filed 14 Aug 2026545,816$3.9M-21,800−3.8%
Alyeska Investment Group, L.P.unchanged · filed 14 Aug 2026365,000$2.6M00.0%
Aristides Capital LLCunchanged · filed 13 Aug 2026218,510$1.6M00.0%
BOOTHBAY FUND MANAGEMENT, LLCreduced · filed 14 Aug 2026189,148$1.4M-67,245−26.2%
CANTOR FITZGERALD, L. P.reduced · filed 14 Aug 2026108,918$786K-79,713−42.3%
31 Dec 2024 – 30 Jun 2026
222528Dec 24Jun 25Sep 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Opaleye Management Inc. Company insider10% owner · last 16 Oct 202649 · 0
Robert James Wills Company insiderDirector · last 21 Aug 20262 · 0
Lauren D'Angelo Company insiderChief Operating Officer · last 19 May 20261 · 0
Bethany Sensenig Company insiderDirector · last 16 Apr 20260 · 0
Kenneth Anthony Cawkell Company insiderDirector · last 14 Jan 20260 · 0
Leonard Powell Mertz Company insiderDirector · last 14 Jan 20262 · 0
Phillip Joseph Mertz Company insiderDirector · last 14 Jan 20260 · 1
Rajeev Kumar Bakshi Company insiderDirector · last 14 Jan 20260 · 0
Huy Du Henry Company insiderVP Finance and Accounting · last 9 Jan 20260 · 0
Michael E. McFadden Company insiderChief Executive Officer · last 9 Jan 20261 · 0
John Prentiss Havens Company insiderDirector · last 25 Feb 20251 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202594.1%
Operating profit marginFY 2025 · to 31 Dec 2025-222%
Free cash flow marginFY 2025 · to 31 Dec 2025-202%
Return on capital employedFY 2025 · to 31 Dec 2025-32.1%
Research spendFY 2025 · to 31 Dec 202518.3%
Share count trendFY 2025 · to 31 Mar 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$66.0M
Free cash flowFY 2025 · to 31 Dec 2025−$20.7M

Analyst forecasts

No analyst forecasts yet.